Lisa Gwynn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lisa Gwynn has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Alberto J. Caban-Martinez
Department of Public Health Sciences University of Miami Miller School of Medicine Miami Florida USA
4 shared publications - Ashley L. Fowlkes
Influenza Division, Centers for Disease Control and Prevention , Atlanta, Georgia
4 shared publications - James Hollister
Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
4 shared publications - Karen Lutrick
University of Arizona College of Medicine , Tucson, Arizona
4 shared publications - Lauren E. W. Olsho
Abt Associates, Rockville, USA
4 shared publications - Manjusha Gaglani
Baylor Scott & White Health , Temple, TX
4 shared publications
Latest Publications
- Open Access
- 19 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e74080
Study protocol of a randomized trial of U-PEACE: An iteratively adapted transdiagnostic prevention program for diverse high school settings (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Despite many adolescents experiencing mental health concerns, a substantial portion lack access to evidence-based treatments (EBTs) for psychopathology; this issue is magnified for adolescents belonging to marginalized communities. One way to ameliorate this is by adapting existent EBTs—typically delivered in research settings —so they are feasible and scalable in locations where adolescents naturally reside, such as high schools. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) may be particularly suited for this purpose due to its transdiagnostic, modular approach and its focus on adolescent clients. Objective: The goal of the study described is to iteratively adapt and implement the UP-A in three Title I high schools—with a focus on feasibility and scalability of the intervention in diverse high school settings. Methods: For initial adaptation, members of participating high school communities will be presented with original pre-adaptation materials and asked to provide qualitative feedback on how to make the program more appropriate and feasible for their schools (Aim 1). After initial adaptations are implemented, an open-trial pilot case series will assess the appropriateness and feasibility of the resulting program: the Unified Protocol for Emotional and Academic Challenges in Education (U-PEACE; Aim 2). Initial outcome data and qualitative feedback from pilot case series participants will then inform final adaptations for the randomized control trial—in which the adapted program will be compared to high schools’ mental health services as usual (Aim 3). The adapted program's effectiveness will be evaluated by employing a mixed methods approach, and feasibility will be preliminarily assessed through cost-effectiveness analyses (Aim 4). Results: Data collection for the study is expected to conclude in May 2025, with primary outcome analyses anticipated to be completed by August 2025. Conclusions: This protocol may serve as a promising guide for adapting youth EBTs in more accessible, diverse settings, as well as result in a useful prevention program for youth with emotional concerns. Clinical Trial: Trial Registration: ClinicalTrials.gov NCT06056674; https://clinicaltrials.gov/study/NCT06056674
- 19 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e74080
Open AccessStudy protocol of a randomized trial of U-PEACE: An iteratively adapted transdiagnostic prevention program for diverse high school settings (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Despite many adolescents experiencing mental health concerns, a substantial portion lack access to evidence-based treatments (EBTs) for psychopathology; this issue is magnified for adolescents belonging to marginalized communities. One way to ameliorate this is by adapting existent EBTs—typically delivered in research settings —so they are feasible and scalable in locations where adolescents naturally reside, such as high schools. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) may be particularly suited for this purpose due to its transdiagnostic, modular approach and its focus on adolescent clients. Objective: The goal of the study described is to iteratively adapt and implement the UP-A in three Title I high schools—with a focus on feasibility and scalability of the intervention in diverse high school settings. Methods: For initial adaptation, members of participating high school communities will be presented with original pre-adaptation materials and asked to provide qualitative feedback on how to make the program more appropriate and feasible for their schools (Aim 1). After initial adaptations are implemented, an open-trial pilot case series will assess the appropriateness and feasibility of the resulting program: the Unified Protocol for Emotional and Academic Challenges in Education (U-PEACE; Aim 2). Initial outcome data and qualitative feedback from pilot case series participants will then inform final adaptations for the randomized control trial—in which the adapted program will be compared to high schools’ mental health services as usual (Aim 3). The adapted program's effectiveness will be evaluated by employing a mixed methods approach, and feasibility will be preliminarily assessed through cost-effectiveness analyses (Aim 4). Results: Data collection for the study is expected to conclude in May 2025, with primary outcome analyses anticipated to be completed by August 2025. Conclusions: This protocol may serve as a promising guide for adapting youth EBTs in more accessible, diverse settings, as well as result in a useful prevention program for youth with emotional concerns. Clinical Trial: Trial Registration: ClinicalTrials.gov NCT06056674; https://clinicaltrials.gov/study/NCT06056674
- Open Access
- 19 March 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Study protocol of a randomized trial of U-PEACE: An iteratively adapted transdiagnostic prevention program for diverse high school settings (Preprint)
BACKGROUND Despite many adolescents experiencing mental health concerns, a substantial portion lack access to evidence-based treatments (EBTs) for psychopathology; this issue is magnified for adolescents belonging to marginalized communities. One way to ameliorate this is by adapting existent EBTs—typically delivered in research settings —so they are feasible and scalable in locations where adolescents naturally reside, such as high schools. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) may be particularly suited for this purpose due to its transdiagnostic, modular approach and its focus on adolescent clients. OBJECTIVE The goal of the study described is to iteratively adapt and implement the UP-A in three Title I high schools—with a focus on feasibility and scalability of the intervention in diverse high school settings. METHODS For initial adaptation, members of participating high school communities will be presented with original pre-adaptation materials and asked to provide qualitative feedback on how to make the program more appropriate and feasible for their schools (Aim 1). After initial adaptations are implemented, an open-trial pilot case series will assess the appropriateness and feasibility of the resulting program: the Unified Protocol for Emotional and Academic Challenges in Education (U-PEACE; Aim 2). Initial outcome data and qualitative feedback from pilot case series participants will then inform final adaptations for the randomized control trial—in which the adapted program will be compared to high schools’ mental health services as usual (Aim 3). The adapted program's effectiveness will be evaluated by employing a mixed methods approach, and feasibility will be preliminarily assessed through cost-effectiveness analyses (Aim 4). RESULTS Data collection for the study is expected to conclude in May 2025, with primary outcome analyses anticipated to be completed by August 2025. CONCLUSIONS This protocol may serve as a promising guide for adapting youth EBTs in more accessible, diverse settings, as well as result in a useful prevention program for youth with emotional concerns. CLINICALTRIAL Trial Registration: ClinicalTrials.gov NCT06056674; https://clinicaltrials.gov/study/NCT06056674
- 19 March 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessStudy protocol of a randomized trial of U-PEACE: An iteratively adapted transdiagnostic prevention program for diverse high school settings (Preprint)
BACKGROUND Despite many adolescents experiencing mental health concerns, a substantial portion lack access to evidence-based treatments (EBTs) for psychopathology; this issue is magnified for adolescents belonging to marginalized communities. One way to ameliorate this is by adapting existent EBTs—typically delivered in research settings —so they are feasible and scalable in locations where adolescents naturally reside, such as high schools. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) may be particularly suited for this purpose due to its transdiagnostic, modular approach and its focus on adolescent clients. OBJECTIVE The goal of the study described is to iteratively adapt and implement the UP-A in three Title I high schools—with a focus on feasibility and scalability of the intervention in diverse high school settings. METHODS For initial adaptation, members of participating high school communities will be presented with original pre-adaptation materials and asked to provide qualitative feedback on how to make the program more appropriate and feasible for their schools (Aim 1). After initial adaptations are implemented, an open-trial pilot case series will assess the appropriateness and feasibility of the resulting program: the Unified Protocol for Emotional and Academic Challenges in Education (U-PEACE; Aim 2). Initial outcome data and qualitative feedback from pilot case series participants will then inform final adaptations for the randomized control trial—in which the adapted program will be compared to high schools’ mental health services as usual (Aim 3). The adapted program's effectiveness will be evaluated by employing a mixed methods approach, and feasibility will be preliminarily assessed through cost-effectiveness analyses (Aim 4). RESULTS Data collection for the study is expected to conclude in May 2025, with primary outcome analyses anticipated to be completed by August 2025. CONCLUSIONS This protocol may serve as a promising guide for adapting youth EBTs in more accessible, diverse settings, as well as result in a useful prevention program for youth with emotional concerns. CLINICALTRIAL Trial Registration: ClinicalTrials.gov NCT06056674; https://clinicaltrials.gov/study/NCT06056674
- Open Access
- 28 January 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (3) , 255
Identifying Caregiving Youth and Associated Mental Health Concerns in a Medical Clinic Setting
Background/ Objectives: Despite the high estimated prevalence and the documented impact of caregiving on children, there is no systematic process to identify or study caregiving youth in the healthcare setting. The aim of this study was to pilot screening in school-based clinics to identify caregiving youth and their associated mental health outcomes. Methods: From March 2021 to March 2022, ninth- to twelfth-grade students were surveyed regarding caregiving and validated mental health screeners during intake at three Title 1 school-based health clinics in Miami, FL. Results: Thirty-nine percent of participants self-identified as caregivers. The most common caregiving tasks were cleaning (n = 20, 50%), keeping company (n = 19, 48%), shopping/cooking (n = 14, 35%), dressing (n = 13, 33%), mobility support (n = 12, 30%), and medical support (n = 11, 28%). Compared to their non-caregiving counterparts, caregiving youth had higher scores on mental health screeners, and caregivers were more likely to endorse clinically significant levels of depression (p = 0.050). Conclusions: Screening in the healthcare system was effective at identifying caregiving youth in school-based clinics whose mental health may be impacted by caregiving responsibilities. Pediatricians should actively screen for both caregiving and mental health concerns. Future studies are needed to ensure the caregiving screening tool is reliable and valid for broad-scale provider use.
- 28 January 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (3) , 255
Open AccessIdentifying Caregiving Youth and Associated Mental Health Concerns in a Medical Clinic Setting
Background/ Objectives: Despite the high estimated prevalence and the documented impact of caregiving on children, there is no systematic process to identify or study caregiving youth in the healthcare setting. The aim of this study was to pilot screening in school-based clinics to identify caregiving youth and their associated mental health outcomes. Methods: From March 2021 to March 2022, ninth- to twelfth-grade students were surveyed regarding caregiving and validated mental health screeners during intake at three Title 1 school-based health clinics in Miami, FL. Results: Thirty-nine percent of participants self-identified as caregivers. The most common caregiving tasks were cleaning (n = 20, 50%), keeping company (n = 19, 48%), shopping/cooking (n = 14, 35%), dressing (n = 13, 33%), mobility support (n = 12, 30%), and medical support (n = 11, 28%). Compared to their non-caregiving counterparts, caregiving youth had higher scores on mental health screeners, and caregivers were more likely to endorse clinically significant levels of depression (p = 0.050). Conclusions: Screening in the healthcare system was effective at identifying caregiving youth in school-based clinics whose mental health may be impacted by caregiving responsibilities. Pediatricians should actively screen for both caregiving and mental health concerns. Future studies are needed to ensure the caregiving screening tool is reliable and valid for broad-scale provider use.
- 27 December 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 959
Wastewater based measures of COVID-19 and associations with children's absenteeism at grade schools
- 27 December 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 959
Wastewater based measures of COVID-19 and associations with children's absenteeism at grade schools
- Open Access
- 13 November 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (3) , 665-676
Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers
While there is evidence that COVID-19 vaccination protects against development of post-COVID conditions (PCC) after severe infection data are limited on whether vaccination reduces the risk after cases of less-severe non-hospitalized COVID-19 disease with more recent SARS-CoV-2 variant viruses. This study assessed whether COVID-19 vaccination was protective against subsequent development of PCC in persons with predominantly mild initial infections during both Delta and Omicron variant predominance. This study utilized a case-control design, nested within the HEROES-RECOVER cohort. Participants aged ≥18 years with PCR-confirmed SARS-CoV-2 infection between 6/28/2021 and 9/14/2022 were surveyed for PCC, defined by symptoms lasting >1 month after initial infection Cases were participants self-reporting PCC and controls were participants that did not self-report PCC. The exposure was mRNA COVID-19 vaccination (2 or 3 monovalent doses) versus no COVID-19 vaccination. Logistic regression was used to compare the odds of PCC among vaccinated and unvaccinated persons; additional analyses evaluating PCC subtypes were also performed. A total of 936 participants with documented SARS-CoV-2 infection were included; of these 23.6% (221) reported PCC and 83.3% (779) were vaccinated. Participants who received a 3rd COVID-19 monovalent mRNA dose prior to infection had lower odds of PCC-related gastrointestinal, neurological, and other symptoms compared to unvaccinated participants (aOR: 0.37; 95% CI: 0.16-0.85; aOR: 0.56; 95% CI: 0.32-0.97; aOR:0.48; 95% CI: 0.25-0.91). COVID-19 vaccination protected against development of PCC among persons with mild infection during both Delta and Omicron variant predominance, supporting vaccination as an important tool for PCC prevention.
- 13 November 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (3) , 665-676
Open AccessAssociation of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers
While there is evidence that COVID-19 vaccination protects against development of post-COVID conditions (PCC) after severe infection data are limited on whether vaccination reduces the risk after cases of less-severe non-hospitalized COVID-19 disease with more recent SARS-CoV-2 variant viruses. This study assessed whether COVID-19 vaccination was protective against subsequent development of PCC in persons with predominantly mild initial infections during both Delta and Omicron variant predominance. This study utilized a case-control design, nested within the HEROES-RECOVER cohort. Participants aged ≥18 years with PCR-confirmed SARS-CoV-2 infection between 6/28/2021 and 9/14/2022 were surveyed for PCC, defined by symptoms lasting >1 month after initial infection Cases were participants self-reporting PCC and controls were participants that did not self-report PCC. The exposure was mRNA COVID-19 vaccination (2 or 3 monovalent doses) versus no COVID-19 vaccination. Logistic regression was used to compare the odds of PCC among vaccinated and unvaccinated persons; additional analyses evaluating PCC subtypes were also performed. A total of 936 participants with documented SARS-CoV-2 infection were included; of these 23.6% (221) reported PCC and 83.3% (779) were vaccinated. Participants who received a 3rd COVID-19 monovalent mRNA dose prior to infection had lower odds of PCC-related gastrointestinal, neurological, and other symptoms compared to unvaccinated participants (aOR: 0.37; 95% CI: 0.16-0.85; aOR: 0.56; 95% CI: 0.32-0.97; aOR:0.48; 95% CI: 0.25-0.91). COVID-19 vaccination protected against development of PCC among persons with mild infection during both Delta and Omicron variant predominance, supporting vaccination as an important tool for PCC prevention.
- Open Access
Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal Cohort
Hybrid immunity, as a result of infection and vaccination to SARS-CoV-2, has been well studied in adults but limited evidence is available in children. We evaluated the antibody responses to primary SARS-CoV-2 infection among vaccinated and unvaccinated children aged ≥ 5 years. Methods: A longitudinal cohort study of children aged ≥ 5 was conducted during August 2021–August 2022, at sites in Arizona, Texas, Utah, and Florida. Children submitted weekly nasal swabs for PCR testing and provided sera 14–59 days after PCR-confirmed SARS-CoV-2 infection. Antibodies were measured by ELISA against the receptor-binding domain (RBD) and S2 domain of ancestral Spike (WA1), in addition to Omicron (BA.2) RBD, following infection in children, with and without prior monovalent ancestral mRNA COVID-19 vaccination. Results: Among the 257 participants aged 5 to 18 years, 166 (65%) had received at least two mRNA COVID-19 vaccine doses ≥ 14 days prior to infection. Of these, 53 occurred during Delta predominance, with 37 (70%) unvaccinated at the time of infection. The remaining 204 infections occurred during Omicron predominance, with 53 (26%) participants unvaccinated. After adjusting for weight, age, symptomatic infection, and gender, significantly higher mean RBD AUC values were observed among the vaccinated group compared to the unvaccinated group for both WA1 and Omicron (p < 0.0001). A smaller percentage of vaccinated children reported fever during illness, with 55 (33%) reporting fever compared to 44 (48%) unvaccinated children reporting fever (p = 0.021). Conclusions: Children with vaccine-induced immunity at the time of SARS-CoV-2 infection had higher antibody levels during convalescence and experienced less fever compared to unvaccinated children during infection.
Open AccessEvaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal Cohort
Hybrid immunity, as a result of infection and vaccination to SARS-CoV-2, has been well studied in adults but limited evidence is available in children. We evaluated the antibody responses to primary SARS-CoV-2 infection among vaccinated and unvaccinated children aged ≥ 5 years. Methods: A longitudinal cohort study of children aged ≥ 5 was conducted during August 2021–August 2022, at sites in Arizona, Texas, Utah, and Florida. Children submitted weekly nasal swabs for PCR testing and provided sera 14–59 days after PCR-confirmed SARS-CoV-2 infection. Antibodies were measured by ELISA against the receptor-binding domain (RBD) and S2 domain of ancestral Spike (WA1), in addition to Omicron (BA.2) RBD, following infection in children, with and without prior monovalent ancestral mRNA COVID-19 vaccination. Results: Among the 257 participants aged 5 to 18 years, 166 (65%) had received at least two mRNA COVID-19 vaccine doses ≥ 14 days prior to infection. Of these, 53 occurred during Delta predominance, with 37 (70%) unvaccinated at the time of infection. The remaining 204 infections occurred during Omicron predominance, with 53 (26%) participants unvaccinated. After adjusting for weight, age, symptomatic infection, and gender, significantly higher mean RBD AUC values were observed among the vaccinated group compared to the unvaccinated group for both WA1 and Omicron (p < 0.0001). A smaller percentage of vaccinated children reported fever during illness, with 55 (33%) reporting fever compared to 44 (48%) unvaccinated children reporting fever (p = 0.021). Conclusions: Children with vaccine-induced immunity at the time of SARS-CoV-2 infection had higher antibody levels during convalescence and experienced less fever compared to unvaccinated children during infection.
- Open Access
- 1 August 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (8) , ofad431
Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5–11 Years in a Multisite Prospective Cohort Study, September 2021–September 2022
The PROTECT study is a longitudinal cohort study initiated in July 2021 with weekly testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 4 states: Arizona, Florida, exas, and Utah. This study aims to examine vaccine-elicited antibody response against postvaccination SARS-CoV-2 infections. Children aged 5–11 years had serum collected 14–59 days after their second dose of monovalent Pfizer-BioNTech coronavirus disease 2019 messenger RNA vaccine. Vaccine-elicited antibodies were measured using the area under the curve (AUC) and end-point titer using enzyme-linked immunosorbent assay (receptor-binding domain [RBD] and S2) and surrogate neutralization assays against ancestral (WA1) and Omicron (BA.2). 79 vaccinated participants (33 [41.7%] female; median age, 8.8 years [standard deviation, 1.9 years]), 48 (60.8%) were from Tucson, Arizona; 64 (81.0%) were non-Hispanic white; 63 (80.8%) attended school in person; 68 (86.1%) did not have any chronic conditions; and 47 (59.5%) were infected after vaccination. Uninfected children had higher AUCs against WA1 (P = .009) and Omicron (P = .02). The geometric mean and surrogate neutralization titer above the limit of detection was 346.0 for WA1 and 39.7 for Omicron, an 8.7-fold decrease (P < .001). After adjustment of covariates in the WA1-specific model, we observed a 47% reduction in the odds of postvaccination infection for every standard deviation increase in RBD AUC (aOR, 0.53 [95% confidence interval, .29–.97) and a 69% reduction in the odds of infection for every 3-fold increase in RBD end titer (0.31 [.06–1.57]). Children with higher antibody levels experienced a lower incidence of postvaccination SARS-CoV-2 infection.
- 1 August 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (8) , ofad431
Open AccessHumoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5–11 Years in a Multisite Prospective Cohort Study, September 2021–September 2022
The PROTECT study is a longitudinal cohort study initiated in July 2021 with weekly testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 4 states: Arizona, Florida, exas, and Utah. This study aims to examine vaccine-elicited antibody response against postvaccination SARS-CoV-2 infections. Children aged 5–11 years had serum collected 14–59 days after their second dose of monovalent Pfizer-BioNTech coronavirus disease 2019 messenger RNA vaccine. Vaccine-elicited antibodies were measured using the area under the curve (AUC) and end-point titer using enzyme-linked immunosorbent assay (receptor-binding domain [RBD] and S2) and surrogate neutralization assays against ancestral (WA1) and Omicron (BA.2). 79 vaccinated participants (33 [41.7%] female; median age, 8.8 years [standard deviation, 1.9 years]), 48 (60.8%) were from Tucson, Arizona; 64 (81.0%) were non-Hispanic white; 63 (80.8%) attended school in person; 68 (86.1%) did not have any chronic conditions; and 47 (59.5%) were infected after vaccination. Uninfected children had higher AUCs against WA1 (P = .009) and Omicron (P = .02). The geometric mean and surrogate neutralization titer above the limit of detection was 346.0 for WA1 and 39.7 for Omicron, an 8.7-fold decrease (P < .001). After adjustment of covariates in the WA1-specific model, we observed a 47% reduction in the odds of postvaccination infection for every standard deviation increase in RBD AUC (aOR, 0.53 [95% confidence interval, .29–.97) and a 69% reduction in the odds of infection for every 3-fold increase in RBD end titer (0.31 [.06–1.57]). Children with higher antibody levels experienced a lower incidence of postvaccination SARS-CoV-2 infection.
- Open Access
Association of Adverse Childhood Experiences with Heart Conditions in Children: Insight from the 2019–2020 National Survey of Children’s Health
Adverse Childhood Experiences (ACEs) have been associated with a higher risk of developing cardiovascular diseases and premature mortality in adults. OBJECTIVES: We evaluated the associations between ACEs and heart diseases among children in the United States. METHODS: Data on children ages 0 to 17 years reported by parents/guardians to have current heart conditions were analyzed. Using Stata version 17 software, descriptive statistics were generated for the demographic characteristics and the various health outcomes using the chi-square of independence. Multivariate logistic regression models were employed to determine the associations between ACEs and heart conditions, the severity of heart conditions, and overall health status. RESULTS: There were 826 children with current heart conditions from a total of 68,753 surveyed children. This corresponded to an estimated 780,000 (1.13%) children living with heart conditions in the U.S. On multivariate logistic models, several ACEs, including household economic hardship, parental/guardian’s alcohol/drug abuse, severe mental health illness of parents/guardians, racial/ethnic discrimination, exposure to neighborhood violence, and accumulation of two or more ACEs, were significantly associated with heart diseases among children. Though the accumulation of two or more ACEs did not have a significant association with the severity of heart condition, it was significantly associated with caregiver reports of undesirable overall health status. CONCLUSIONS: ACEs are significantly associated with heart conditions among children and contribute to unfavorable overall health status among children with heart conditions in the U.S. There is a need for policies and programs that will promptly identify ACEs and mitigate their negative impact on children.
Open AccessAssociation of Adverse Childhood Experiences with Heart Conditions in Children: Insight from the 2019–2020 National Survey of Children’s Health
Adverse Childhood Experiences (ACEs) have been associated with a higher risk of developing cardiovascular diseases and premature mortality in adults. OBJECTIVES: We evaluated the associations between ACEs and heart diseases among children in the United States. METHODS: Data on children ages 0 to 17 years reported by parents/guardians to have current heart conditions were analyzed. Using Stata version 17 software, descriptive statistics were generated for the demographic characteristics and the various health outcomes using the chi-square of independence. Multivariate logistic regression models were employed to determine the associations between ACEs and heart conditions, the severity of heart conditions, and overall health status. RESULTS: There were 826 children with current heart conditions from a total of 68,753 surveyed children. This corresponded to an estimated 780,000 (1.13%) children living with heart conditions in the U.S. On multivariate logistic models, several ACEs, including household economic hardship, parental/guardian’s alcohol/drug abuse, severe mental health illness of parents/guardians, racial/ethnic discrimination, exposure to neighborhood violence, and accumulation of two or more ACEs, were significantly associated with heart diseases among children. Though the accumulation of two or more ACEs did not have a significant association with the severity of heart condition, it was significantly associated with caregiver reports of undesirable overall health status. CONCLUSIONS: ACEs are significantly associated with heart conditions among children and contribute to unfavorable overall health status among children with heart conditions in the U.S. There is a need for policies and programs that will promptly identify ACEs and mitigate their negative impact on children.
- Open Access
- 28 July 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (7) , e37929
Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study
Background: Assessing the real-world effectiveness of COVID-19 vaccines and understanding the incidence and severity of SARS-CoV-2 illness in children are essential to inform policy and guide health care professionals in advising parents and caregivers of children who test positive for SARS-CoV-2. Objective: This report describes the objectives and methods for conducting the Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT) study. PROTECT is a longitudinal prospective pediatric cohort study designed to estimate SARS-CoV-2 incidence and COVID-19 vaccine effectiveness (VE) against infection among children aged 6 months to 17 years, as well as differences in SARS-CoV-2 infection and vaccine response between children and adolescents. Methods: The PROTECT multisite network was initiated in July 2021, which aims to enroll approximately 2305 children across four US locations and collect data over a 2-year surveillance period. The enrollment target was based on prospective power calculations and accounts for expected attrition and nonresponse. Study sites recruit parents and legal guardians of age-eligible children participating in the existing Arizona Healthcare, Emergency Response, and Other Essential Workers Surveillance (HEROES)-Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) network as well as from surrounding communities. Child demographics, medical history, COVID-19 exposure, vaccination history, and parents/legal guardians’ knowledge and attitudes about COVID-19 are collected at baseline and throughout the study. Mid-turbinate nasal specimens are self-collected or collected by parents/legal guardians weekly, regardless of symptoms, for SARS-CoV-2 and influenza testing via reverse transcription-polymerase chain reaction (RT-PCR) assay, and the presence of COVID-like illness (CLI) is reported. Children who test positive for SARS-CoV-2 or influenza, or report CLI are monitored weekly by online surveys to report exposure and medical utilization until no longer ill. Children, with permission of their parents/legal guardians, may elect to contribute blood at enrollment, following SARS-CoV-2 infection, following COVID-19 vaccination, and at the end of the study period. PROTECT uses electronic medical record (EMR) linkages where available, and verifies COVID-19 and influenza vaccinations through EMR or state vaccine registries. Results: Data collection began in July 2021 and is expected to continue through the spring of 2023. As of April 13, 2022, 2371 children are enrolled in PROTECT. Enrollment is ongoing at all study sites. Conclusions: As COVID-19 vaccine products are authorized for use in pediatric populations, PROTECT study data will provide real-world estimates of VE in preventing infection. In addition, this prospective cohort provides a unique opportunity to further understand SARS-CoV-2 incidence, clinical course, and key knowledge gaps that may inform public health. International Registered Report Identifier (IRRID): RR1-10.2196/37929
- 28 July 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (7) , e37929
Open AccessPediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study
Background: Assessing the real-world effectiveness of COVID-19 vaccines and understanding the incidence and severity of SARS-CoV-2 illness in children are essential to inform policy and guide health care professionals in advising parents and caregivers of children who test positive for SARS-CoV-2. Objective: This report describes the objectives and methods for conducting the Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT) study. PROTECT is a longitudinal prospective pediatric cohort study designed to estimate SARS-CoV-2 incidence and COVID-19 vaccine effectiveness (VE) against infection among children aged 6 months to 17 years, as well as differences in SARS-CoV-2 infection and vaccine response between children and adolescents. Methods: The PROTECT multisite network was initiated in July 2021, which aims to enroll approximately 2305 children across four US locations and collect data over a 2-year surveillance period. The enrollment target was based on prospective power calculations and accounts for expected attrition and nonresponse. Study sites recruit parents and legal guardians of age-eligible children participating in the existing Arizona Healthcare, Emergency Response, and Other Essential Workers Surveillance (HEROES)-Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) network as well as from surrounding communities. Child demographics, medical history, COVID-19 exposure, vaccination history, and parents/legal guardians’ knowledge and attitudes about COVID-19 are collected at baseline and throughout the study. Mid-turbinate nasal specimens are self-collected or collected by parents/legal guardians weekly, regardless of symptoms, for SARS-CoV-2 and influenza testing via reverse transcription-polymerase chain reaction (RT-PCR) assay, and the presence of COVID-like illness (CLI) is reported. Children who test positive for SARS-CoV-2 or influenza, or report CLI are monitored weekly by online surveys to report exposure and medical utilization until no longer ill. Children, with permission of their parents/legal guardians, may elect to contribute blood at enrollment, following SARS-CoV-2 infection, following COVID-19 vaccination, and at the end of the study period. PROTECT uses electronic medical record (EMR) linkages where available, and verifies COVID-19 and influenza vaccinations through EMR or state vaccine registries. Results: Data collection began in July 2021 and is expected to continue through the spring of 2023. As of April 13, 2022, 2371 children are enrolled in PROTECT. Enrollment is ongoing at all study sites. Conclusions: As COVID-19 vaccine products are authorized for use in pediatric populations, PROTECT study data will provide real-world estimates of VE in preventing infection. In addition, this prospective cohort provides a unique opportunity to further understand SARS-CoV-2 incidence, clinical course, and key knowledge gaps that may inform public health. International Registered Report Identifier (IRRID): RR1-10.2196/37929
- 24 February 2021
- Published by American Academy of Pediatrics (AAP)
- Vol. 147 (3 MeetingA) , 5
An Examination of Miami-Dade County Public-School Vaccination Compliance Utilizing GIS Mapping
- 24 February 2021
- Published by American Academy of Pediatrics (AAP)
- Vol. 147 (3 MeetingA) , 5
An Examination of Miami-Dade County Public-School Vaccination Compliance Utilizing GIS Mapping